Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Chronic Graft-Versus-Host Disease
NCT04198922Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2020
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), sponsored by Fred Hutchinson Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
Beyond the preview
Go deeper on NCT04198922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198922.